Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for OrbusNeich Medical Group Holdings's Debt-to-EBITDA or its related term are showing as below:
FRA:Q8T'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07 Med: 0.15 Max: 8.15
Current: 0.13
During the past 7 years, the highest Debt-to-EBITDA Ratio of OrbusNeich Medical Group Holdings was 8.15. The lowest was 0.07. And the median was 0.15.
FRA:Q8T's Debt-to-EBITDA is ranked better than 88.4% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 1.595
vs FRA:Q8T: 0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
OrbusNeich Medical Group Holdings Debt-to-EBITDA Related Terms
OrbusNeich Medical Group Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrbusNeich Medical Group Holdings Debt-to-EBITDA Chart
FRA:Q8T vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrbusNeich Medical Group Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OrbusNeich Medical Group Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Debt-to-EBITDA of 0.07 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OrbusNeich Medical Group Holdings. This is 53% below median its historical median of 0.15. Over the past decade, OrbusNeich Medical Group Holdings' Debt-to-EBITDA has ranged from 0.07 to 8.15. According to the industry distribution chart, OrbusNeich Medical Group Holdings ranks #55 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is OrbusNeich Medical Group Holdings' Debt-to-EBITDA too high?
OrbusNeich Medical Group Holdings' current Debt-to-EBITDA of 0.07 is 53% below median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 8.15. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. OrbusNeich Medical Group Holdings' value of 0.07 is 95.6% below this industry median. Based on the distribution chart, OrbusNeich Medical Group Holdings ranks #55 out of 474 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, OrbusNeich Medical Group Holdings ranks #55 out of 474 companies for Debt-to-EBITDA. This places OrbusNeich Medical Group Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.60. OrbusNeich Medical Group Holdings' value of 0.07 is 95.6% below this benchmark. Historically, OrbusNeich Medical Group Holdings' own Debt-to-EBITDA has ranged from 0.07 to 8.15 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 1.60, OrbusNeich Medical Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrbusNeich Medical Group Holdings's current Debt-to-EBITDA of 0.07 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on OrbusNeich Medical Group Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrbusNeich Medical Group Holdings's current Debt-to-EBITDA is 0.07, which is 53% below median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Debt-to-EBITDA of 0.07. The stock's GF Value™ is €0.49, compared to a current price of €0.37 — trading 23.7% below its estimated fair value. The current Debt-to-EBITDA is 0.07, which is 53% below median its 10-year median of 0.15 and 95.6% below the Medical Devices & Instruments industry median of 1.60. OrbusNeich Medical Group Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Debt-to-EBITDA is 0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?
Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued.
The current stock price of €0.37 is trading 23.7% below its estimated GF Value™ of €0.49.
Key valuation signals for FRA:Q8T:
Debt-to-EBITDA: 0.07 (53% below median its 10-year median of 0.15)
GF Value™: €0.49 vs. price of €0.37 (23.7% below fair value)
Industry Position: 95.6% below the Medical Devices & Instruments median (#55 of 474)
No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
95GF Score
Get the complete analysis for FRA:Q8T
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q8T has been successfully added to your 
